individuals undergoing immunosuppressive treatment such as corticosteroids or chemotherapy, as well as patients with autoimmune disorders
Starting when drugs like semaglutide and tirzepatide went into shortage, Hims began selling compounded GLP-1 injections in May 2024, taking advantage of a regulatory provision allowing compounding of drugs on the FDAs official shortage list
Priced at $199 per month, these injections contain the same active ingredient as branded versions but at a fraction of the cost
But were going to break it all down
These medications work through multiple body systems simultaneously, creating a comprehensive approach to weight loss that addresses both physiological and neurological factors
According to the company's published terms, they follow a no-refund policy unless the product is proven to be not as described or faulty